細胞生存アッセイの市場規模、シェア、動向分析レポート：製品別（消耗品、機器）、用途別（創薬・開発、幹細胞研究）、エンドユーザー別、地域別、セグメント別予測、2023年～2030年

細胞生存アッセイ市場の成長と動向

Grand View Research, Inc.の最新レポートによると、細胞生存アッセイの世界市場規模は2030年までに30億1000万米ドルに達し、2023年から2030年までCAGR9.94%で拡大すると予測されています。慢性疾患や感染症の有病率が上昇し、細胞ベースの治療薬への注目が高まっていることが、同市場の成長見通しを拡大させています。また、細胞ベース研究のための資金調達の増加や自動化機器の使用の増加が、細胞生存アッセイ（CVA）の市場を牽引する主な要因となっています。

細胞ベースの研究のための資金調達と投資の増加は、細胞生存アッセイの成長見通しを拡大しています。例えば、2022年5月、カリフォルニア再生医療研究所（CIRM）は、咽頭がん患者が放射線療法の壊滅的な副作用から治癒するのを助けるための細胞療法臨床試験テストに1100万米ドルを投資すると発表しました。このように、細胞ベースの研究に対する資金提供の増加は、予測期間中の市場成長を後押しすると予想されます。

さらに、主要企業は、需要の高まりに対応し、未開拓の機会を獲得するために、洗練された技術を継続的に開発しています。例えば、2022年4月、Molecular Devices, LLCは、細胞の生存率を含む様々なアプリケーションのためのSpectraMax Mini Multi-Mode Microplate Readerを発表しました。これは、データ解析ソフトウェアとプロトコル制御を統合したコンパクトで費用対効果の高いソリューションで、迅速なデータ生成と解析が可能です。このような技術革新により、バイオテクノロジーや学術研究室でのCVAの採用が進むと予想されます。

COVID-19の大流行が市場成長にプラスの影響を与えると予想されます。細胞計数および生存率アッセイは、COVID-19ワクチン研究を支援するために使用されます。COVID-19研究で最も頻繁に使用されるCVAには、Live/Dead（EarlyTox Live/Dead Assay Kit）staining, MTT assay, Transfection efficiency, and Cell viability（CellTiter-Glo Luminescent Cell Viability Assay）が含まれます。その結果、COVID-19の流行により、これらのアッセイの使用量が増加すると予測され、市場の成長を押し上げると予想されます。

細胞ベースの治療薬の開発への注目が高まっていることが、市場の成長を加速させています。臨床試験の増加、FDAの承認、大手企業による提携などの戦略的な取り組みが、市場成長を後押ししています。例えば、2022年1月、ブリストル・マイヤーズスクイブとセンチュリー・セラピューティクスは、血液悪性腫瘍と固形腫瘍のための4つの人工多能性幹細胞を開発するための研究協力に入りました。このような取り組みにより、幹細胞治療薬の開発におけるCVAの適用が増加し、予測期間中の成長を促進すると予測されます。

一方、試薬のコストが高いことや、3次元細胞培養における細胞生存率測定法の適用に制限があることが、市場の成長をある程度制限する可能性があります。例えば、3次元細胞培養で細胞生存アッセイを行う場合、アッセイ試薬がマイクロティッシュの中心に到達することが困難な場合があります。そのため、正確な測定結果を得ることができないです。しかし、主要企業はこの限界を克服するために、新規かつ費用対効果の高い試薬や技術の開発に継続的に取り組んでおり、これが市場の成長見通しを生み出すと思われます。

細胞生存アッセイ市場のレポートハイライト

製品別では、消耗品部門が2022年に最大のシェアを占めました。これは、製薬会社やバイオテクノロジー企業、幹細胞研究、診断におけるCVAへの要求が高まっていることに起因しており、ひいては市場の成長を後押しするものと思われます

用途別では、創薬・開発分野が2022年に2位のシェアを占めました。これは、創薬・開発時の細胞死に関連する細胞変動を推定するCVAの用途が増加したことに起因している

エンドユーザー別では、開発薬剤の細胞への影響を評価するために、医薬品における細胞生存率測定法が広く使用されていることから、バイオ医薬品および製薬会社セグメントが2022年に最大のシェアを占めました。

政府による投資イニシアティブの増加、がんなどの慢性疾患の発生率の増加、臨床および研究所研究のための高品質なインフラの存在により、2022年には北米が35.0%以上のシェアで世界市場を独占しました。

アジア太平洋地域は、新規治療薬に対する需要の高まり、政府による研究開発投資の増加、急速なインフラ整備により、将来的に大幅な成長が見込まれています。

目次

第1章 調査手法

• 市場セグメンテーションと範囲
• 調査手法
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国別の市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報一覧
• 一次情報のリスト
• 目的
• 略語一覧

第2章 市場の定義

第3章 エグゼクティブサマリー

• 市場概要

第4章 世界の細胞生存アッセイ市場の変数、動向、および範囲

• 細胞生存アッセイ市場系統の見通し
  • 親市場の見通し
• 浸透と成長の見通しのマッピング
• 規制の枠組み
• 市場促進要因分析
  • 細胞ベースの治療法の開発への注目が高まっています
  • 細胞ベースの調査に対する資金の増加
  • 細胞生存アッセイにおける技術の進歩
• 市場抑制要因分析
  • 試薬や機器のコストが高いため、細胞生存アッセイの採用が制限される可能性があります
  • 3D細胞培養のための細胞生存アッセイの適用性の制限
• 市場機会分析
  • 幹細胞調査への注目の高まり
• ポーターのファイブフォース分析
• 細胞生存アッセイ市場：COVID-19影響分析

第5章 細胞生存アッセイ市場-セグメント分析、製品別、2018年から2030年（100万米ドル）

• 世界の細胞生存アッセイ市場：製品変動分析
• 消耗品
  • 試薬およびアッセイキット
    • 色素排除アッセイ
    • 比色アッセイ
    • 蛍光アッセイ
    • ルミノメトリックアッセイ
  • マイクロプレート
• 機器
  • 分光光度計
  • 顕微鏡検査
  • 細胞画像解析システム
  • フローサイトメトリー
  • その他

第6章 細胞生存アッセイ市場-セグメント分析、アプリケーション別、2018年から2030年（100万米ドル）

• 世界の細胞生存アッセイ市場：アプリケーションの変動分析
• 創薬と開発
• 幹細胞調査
• 診断

第7章 細胞生存アッセイ市場-セグメント分析、エンドユーザー別、2018年から2030年（100万米ドル）

• 細胞生存アッセイ市場：エンドユーザーの変動分析
• バイオ医薬品および製薬会社
• CROとCMO
• 学術・調査機関
• 診断ラボ

第8章 細胞生存アッセイ市場：-セグメント分析、地域別、2018年-2030年（100万米ドル）

• 細胞生存アッセイ市場：地域変動分析
• 北米
  • SWOT分析
  • 米国
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • カナダ
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 欧州
  • SWOT分析
  • ドイツ
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 英国
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • フランス
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • イタリア
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スペイン
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • デンマーク
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スウェーデン
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • ノルウェー
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• アジア太平洋地域
  • SWOT分析
  • 日本
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 中国
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • インド
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 韓国
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • オーストラリア
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • タイ
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• ラテンアメリカ
  • SWOT分析
  • ブラジル
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • メキシコ
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アルゼンチン
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 中東・アフリカ
  • SWOT分析
  • 南アフリカ
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • サウジアラビア
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アラブ首長国連邦
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • クウェート
    • 主要国の力学
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ

第9章 競合情勢

• 市場参入企業の概要
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories Inc.
  • Merck KGaA
  • BD
  • PerkinElmer Inc.
  • Promega Corporation
  • Biotium
  • Creative Bioarray
  • Abcam Plc
  • Charles River Laboratories
• 財務実績
• 参加者の分類
  • 市場のリーダー
    • 細胞生存アッセイの市場シェア分析、2022年
  • 戦略マッピング
    • 拡張
    • 取得
    • コラボレーション
    • 製品・サービスのローンチ
    • パートナーシップ
    • その他

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 4. Global cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 5. Global cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 6. Global cell viability assay market, by region, 2018 - 2030 (USD Million)
• Table 7. North America cell viability assay market, by country, 2018 - 2030 (USD Million)
• Table 8. North America cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 9. North America cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 10. North America cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 11. U.S. Cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 12. U.S. Cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 13. U.S. Cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 14. Canada cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 15. Canada cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 16. Canada cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 17. Europe cell viability assay market, by country, 2018 - 2030 (USD Million)
• Table 18. Europe cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 19. Europe cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 20. Europe cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 21. U.K. cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 22. U.K. cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 23. U.K. cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 24. Germany cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 25. Germany cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 26. Germany cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 27. France cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 28. France cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 29. France cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 30. Italy cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 31. Italy cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 32. Italy cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 33. Spain cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 34. Spain cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 35. Spain cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 36. Denmark cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 37. Denmark cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 38. Denmark cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 39. Sweden cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 40. Sweden cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 41. Sweden cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 42. Norway cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 43. Norway cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 44. Norway cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 45. Asia Pacific cell viability assay market, by country, 2018 - 2030 (USD Million)
• Table 46. Asia Pacific cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 47. Asia Pacific cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 48. Asia pacific cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 49. China cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 50. China cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 51. China cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 52. India cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 53. India cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 54. India cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 55. Japan cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 56. Japan cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 57. Japan cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 58. Thailand cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 59. Thailand cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 60. Thailand cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 61. Australia cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 62. Australia cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 63. Australia cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 64. South Korea cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 65. South Korea cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 66. South Korea cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 67. Latin America cell viability assay market, by country, 2018 - 2030 (USD Million)
• Table 68. Latin America cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 69. Latin America cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 70. Latin America cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 71. Brazil cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 72. Brazil cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 73. Brazil cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 74. Mexico cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 75. Mexico cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 76. Mexico cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 77. Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 78. Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 79. Argentina cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 80. Middle East & Africa cell viability assay market, by country, 2018 - 2030 (USD Million)
• Table 81. Middle East & Africa cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 82. Middle East & Africa cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 83. Middle East & Africa cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 84. South Africa cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 85. South Africa cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 86. South Africa cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 87. Saudi Arabia cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 88. Saudi Arabia cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 89. Saudi Arabia cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 90. UAE cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 91. UAE cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 92. UAE cell viability assay market, end-user, 2018 - 2030 (USD Million)
• Table 93. Kuwait cell viability assay market, by product, 2018 - 2030 (USD Million)
• Table 94. Kuwait cell viability assay market, by application, 2018 - 2030 (USD Million)
• Table 95. Kuwait cell viability assay market, end-user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Cell viability assay, market segmentation
• Fig. 8 Market snapshot, 2021
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 Market challenge relevance analysis (current & future impact)
• Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 14 Porter's five forces analysis
• Fig. 15 Market penetration vs growth prospect mapping, 2021
• Fig. 16 Global cell viability assay market: product movement analysis
• Fig. 17 Global cell viability assay market, for consumables, 2018 - 2030 (USD Million)
• Fig. 18 Global cell viability assay market, for reagents and assay kits, by type, 2018 - 2030 (USD Million)
• Fig. 19 Global cell viability assay market, for dye exclusion assays, 2018 - 2030 (USD Million)
• Fig. 20 Global cell viability assay market, for colorimetric assays, 2018 - 2030 (USD Million)
• Fig. 21 Global cell viability assay market, for fluorometric assays, 2018 - 2030 (USD Million)
• Fig. 22 Global cell viability assay market, for luminometric assays, 2018 - 2030 (USD Million)
• Fig. 23 Global cell viability assay market, for microplates, 2018 - 2030 (USD Million)
• Fig. 24 Global cell viability assay market, for insturments, 2018 - 2030 (USD Million)
• Fig. 25 Global cell viability assay market, for spectrophotometer, 2018 - 2030 (USD Million)
• Fig. 26 Global cell viability assay market, for microscopy, 2018 - 2030 (USD Million)
• Fig. 27 Global cell viability assay market, for cell imaging and analysis system, 2018 - 2030 (USD Million)
• Fig. 28 Global cell viability assay market, for others, 2018 - 2030 (USD Million)
• Fig. 29 Global cell viability assay market, for microplates, 2018 - 2030 (USD Million)
• Fig. 30 Global cell viability assay market: application movement analysis
• Fig. 31 Global cell viability assay market, for drug discovery and development, 2018 - 2030 (USD Million)
• Fig. 32 Global cell viability assay market, for stem cell research, 2018 - 2030 (USD Million)
• Fig. 33 Global cell viability assay market, for stem cell research, 2018 - 2030 (USD Million)
• Fig. 34 Global cell viability assay market: end-user movement analysis
• Fig. 35 Global cell viability assay market, for biopharmaceutical & pharmaceutical companies, 2018 - 2030 (USD Million)
• Fig. 36 Global cell viability assay market, for CROSs & CMOs, 2018 - 2030 (USD Million)
• Fig. 37 Global cell viability assay market, for academic & research institutes, 2018 - 2030 (USD Million)
• Fig. 38 Global cell viability assay market, for diagnostic labs, 2018 - 2030 (USD Million)
• Fig. 39 Regional marketplace: key takeaways
• Fig. 40 Regional outlook, 2021 & 2030
• Fig. 41 Global flow cytometry market: regional movement analysis
• Fig. 42 North America cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 43 U.S. Cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 44 Canada cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 45 Europe cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 46 U.K. cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 47 Germany cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 48 France cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 49 Italy cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 50 Spain cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 51 Denmark cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 52 Sweden cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 53 Norway cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 54 Asia pacific cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 55 China cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 56 India cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 57 Japan cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 58 Thailand cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 59 Australia cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 60 South Korea cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 61 Latin America cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 62 Brazil cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 63 Mexico cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 64 Argentina cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 65 Middle East and Africa cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 66 South Africa cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 67 Saudi Arabia cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 68 UAE cell viability assay market, 2018 - 2030 (USD Million)
• Fig. 69 Kuwait cell viability assay market, 2018 - 2030 (USD Million)

Cell Viability Assays Market Growth & Trends:

The global cell viability assays market size is expected to reach USD 3.01 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.94% from 2023 to 2030. The rising prevalence of chronic and infectious diseases and the increasing focus on cell-based therapeutics are expanding the growth prospects of the market. In addition, growing funding for cell-based research and increasing use of automated instruments are the key factors driving the market for cell viability assays (CVAs).

Increasing funding and investments for cell-based research are expanding growth prospects for cell viability assays. For instance, in May 2022, the California Institute for Regenerative Medicine (CIRM) announced an investment of USD 11 million to fund a cell therapy clinical trial testing to help throat cancer patients to heal from the devastating side effects of radiation therapy. Thus, increasing funding for cell-based research is predicted to boost market growth during the projection period.

Furthermore, major players are continuously developing sophisticated technologies to meet the rising demand and capture untapped opportunities. For instance, in April 2022, Molecular Devices, LLC introduced SpectraMax Mini Multi-Mode Microplate Reader for various applications, including cell viability. It is a compact and cost-effective solution integrated with data analysis software and protocol control for rapid data generation and analysis. Such technological innovations are anticipated to increase the adoption of CVAs in biotech and academic laboratories.

The COVID-19 pandemic is expected to positively influence market growth. The cell counting and viability assay are used to aid COVID-19 vaccine research. The most frequently used CVAs in COVID-19 research include Live/Dead (EarlyTox Live/Dead Assay Kit) staining, MTT assay, Transfection efficiency, and Cell viability (CellTiter-Glo Luminescent Cell Viability Assay). As a result, the usage of these assays is projected to increase due to the COVID-19 pandemic, which, in turn, is anticipated to boost the market growth.

The rising focus on the development of cell-based therapeutics is accelerating market growth. Increasing clinical trials, FDA approvals, and strategic initiatives such as collaborations by major players are boosting the market growth. For instance, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a research collaboration to develop four induced pluripotent stem cells for hematologic malignancies and solid tumors. Such initiatives are projected to increase the application of CVAs during the development of stem cell therapeutics, thereby propelling growth during the forecast years.

On the other hand, the high cost of reagents and limitations in the applicability of cell viability assay for 3D cell culture may restrict the market growth to a certain extent. For instance, while performing the cell viability assay in 3D cell culture, the assay regents may have difficulty reaching the center of microtissues. Thus, accurate results of the assay cannot be determined. However, key players are continuously striving for developing novel and cost-effective reagents and techniques to overcome the limitations, which is likely to create growth prospects for the market.

Cell Viability Assays Market Report Highlights:

• By product, the consumables segment held the largest share in 2022. This is attributed to the increase in the requirement of CVAs for pharmaceutical and biotechnology companies, stem cell research, and diagnostics, which, in turn, is likely to fuel the market growth

• By application, the drug discovery and development segment held the second-largest share in 2022. This is attributed to an increase in the applications of CVAs to estimate the cellular variations related to cell death during the drug discovery and development

• By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cell viability assay in pharmaceuticals to evaluate the influence of developed agents on cells

• North America dominated the global market with over 35.0% share in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and the presence of high-quality infrastructure for clinical and laboratory research

• Asia Pacific is expected to grow considerably in the future owing to the rising demand for novel therapeutics, increasing R&D investment by governments, and rapid infrastructural development

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market Segmentation & Scope
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
    • 1.6.1.2 Approach 2: Country-wise market estimation using a bottom-up approach
• 1.7 Global Market: CAGR Calculation
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 List of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1:
  • 1.11.2 Objective 2:
• 1.12 List of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

• 3.1 Market Summary

Chapter 4 Global Cell Viability Assay Market Variables, Trends, & Scope

• 4.1 Cell Viability Assay Market Lineage Outlook
  • 4.1.1 Parent Market Outlook
• 4.2 Penetration and Growth Prospect Mapping
• 4.3 Regulatory Framework
• 4.4 Market Driver Analysis
  • 4.4.1 Rising focus on the development of cell-based therapeutics
  • 4.4.2 Growing funding for cell-based research
  • 4.4.3 Technological advancements in cell viability assays
• 4.5 Market Restraint Analysis
  • 4.5.1 High cost of reagents and instruments may limit the adoption of cell viability assays
  • 4.5.2 Limitations in the applicability of cell viability assays for 3D cell culture
• 4.6 Market Opportunity Analysis
  • 4.6.1 Growing emphasis on stem cell research
• 4.7 Porter's Five Forces Analysis
• 4.8 Cell Viability Assay Market: COVID-19 Impact Analysis

Chapter 5 Cell Viability Assay Market - Segment Analysis, by product, 2018 - 2030 (USD Million)

• 5.1 Global Cell Viability Assay Market: Product Movement Analysis
• 5.2 Consumables
  • 5.2.1 Consumables market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.2.2 Reagents and Assay Kits
    • 5.2.2.1 Reagents and assay kits, by type market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2.2 Dye exclusion assays
    • 5.2.2.2.1 Dye exclusion assays market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2.3 Colorimetric assays
    • 5.2.2.3.1 Colorimetric assays market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2.4 Fluorometric assays
    • 5.2.2.4.1 Fluorometric assays market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2.5 Luminometric assays
    • 5.2.2.5.1 Luminometric assays market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.2.3 Microplates
    • 5.2.2.1 Microplates market estimates and forecast, 2018 - 2030 (USD Million)
• 5.3 Instruments
  • 5.3.1 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.2 Spectrophotometer
    • 5.3.2.1 Spectrophotometer market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.3 Microscopy
    • 5.3.3.1 Microscopy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.4 Cell Imaging and Analysis System
    • 5.3.4.1 Cell imaging and analysis system market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.5 Flow Cytometry
    • 5.3.5.1 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.6 Others
    • 5.3.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cell Viability Assay Market- Segment Analysis, by Application, 2018 - 2030 (USD Million)

• 6.1 Global Cell Viability Assay Market: Application Movement Analysis
• 6.2 Drug Discovery and Development
  • 6.2.1 Drug discovery and development market estimates and forecast, 2018 - 2030 (USD Million)
• 6.3 Stem Cell Research
  • 6.3.1 Stem cell research market estimates and forecast, 2018 - 2030 (USD Million)
• 6.4 Diagnostics
  • 6.4.1 Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cell Viability Assay Market- Segment Analysis, by End-user, 2018 - 2030 (USD Million)

• 7.1 Cell Viability Assay Market: End-user Movement Analysis
• 7.2 Biopharmaceutical & Pharmaceutical Companies
  • 7.2.1 Biopharmaceutical & pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
• 7.3 CROs & CMOs
  • 7.3.1 CROs & CMOs market estimates and forecast, 2018 - 2030 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1 Academic & research institutes market estimates and forecast, 2018 - 2030 (USD Million)
• 7.5. Diagnostic Labs
  • 7.5.1 Diagnostic labs market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cell Viability Assay Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

• 8.1 Cell Viability Assay Market: Regional Movement Analysis
• 8.2 North America
  • 8.2.1 SWOT Analysis
    • 8.2.1.1 North America cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.2.1.2 North America cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.2.1.3 North America cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.2.2 U.S.
    • 8.2.2.1 Key Country Dynamics
    • 8.2.2.2 Target Disease Prevalence
    • 8.2.2.3 Competitive Scenario
    • 8.2.2.4 Regulatory Framework
    • 8.2.2.5 Reimbursement Scenario
    • 8.2.2.6 U.S. cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.2.2.7 U.S. cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.2.2.8 U.S. cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.2.3 Canada
    • 8.2.3.1 Key Country Dynamics
    • 8.2.3.2 Target Disease Prevalence
    • 8.2.3.3 Competitive Scenario
    • 8.2.3.4 Regulatory Framework
    • 8.2.3.5 Reimbursement Scenario
    • 8.2.3.6 Canada cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.2.3.7 Canada cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.2.3.8 Canada cell viability assay market, by end-user, 2018 - 2030 (USD Million)
• 8.3 Europe
  • 8.3.1 SWOT Analysis
    • 8.3.1.1 Europe cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.1.2 Europe cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.1.4 Europe cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.2 Germany
    • 8.3.2.1 Key Country Dynamics
    • 8.3.2.2 Target Disease Prevalence
    • 8.3.2.3 Competitive Scenario
    • 8.3.2.4 Regulatory Framework
    • 8.3.2.5 Reimbursement Scenario
    • 8.3.2.6 Germany cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.2.7 Germany cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.2.8 Germany cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.3 U.K.
    • 8.3.3.1 Key Country Dynamics
    • 8.3.3.2 Target Disease Prevalence
    • 8.3.3.3 Competitive Scenario
    • 8.3.3.4 Regulatory Framework
    • 8.3.3.5 Reimbursement Scenario
    • 8.3.3.6 U.K. cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.3.7 U.K. cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.3.8 U.K. cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.4 France
    • 8.3.4.1 Key Country Dynamics
    • 8.3.4.2 Target Disease Prevalence
    • 8.3.4.3 Competitive Scenario
    • 8.3.4.4 Regulatory Framework
    • 8.3.4.5 Reimbursement Scenario
    • 8.3.4.6 France cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.4.7 France cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.4.8 France cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.5 Italy
    • 8.3.5.1 Key Country Dynamics
    • 8.3.5.2 Target Disease Prevalence
    • 8.3.5.3 Competitive Scenario
    • 8.3.5.4 Regulatory Framework
    • 8.3.5.5 Reimbursement Scenario
    • 8.3.5.6 Italy cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.5.7 Italy cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.5.8 Italy cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.6 Spain
    • 8.3.6.1 Key Country Dynamics
    • 8.3.6.2 Target Disease Prevalence
    • 8.3.6.3 Competitive Scenario
    • 8.3.6.4 Regulatory Framework
    • 8.3.6.5 Reimbursement Scenario
    • 8.3.6.6 Spain cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.6.7 Spain cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.6.8 Spain cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.7 Denmark
    • 8.3.7.1 Key Country Dynamics
    • 8.3.7.2 Target Disease Prevalence
    • 8.3.7.3 Competitive Scenario
    • 8.3.7.4 Regulatory Framework
    • 8.3.7.5 Reimbursement Scenario
    • 8.3.7.6 Denmark cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.7.7 Denmark cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.7.8 Denmark cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.8 Sweden
    • 8.3.8.1 Key Country Dynamics
    • 8.3.8.2 Target Disease Prevalence
    • 8.3.8.3 Competitive Scenario
    • 8.3.8.4 Regulatory Framework
    • 8.3.8.5 Reimbursement Scenario
    • 8.3.8.6 Sweden cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.8.7 Sweden cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.8.8 Sweden cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3.9 Norway
    • 8.3.9.1 Key Country Dynamics
    • 8.3.9.2 Target Disease Prevalence
    • 8.3.9.3 Competitive Scenario
    • 8.3.9.4 Regulatory Framework
    • 8.3.9.5 Reimbursement Scenario
    • 8.3.9.6 Norway cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.3.9.7 Norway cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.3.9.8 Norway cell viability assay market, by end-user, 2018 - 2030 (USD Million)
• 8.4 Asia Pacific
  • 8.4.1 SWOT Analysis
    • 8.4.1.1 Asia Pacific cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.4.1.2 Asia Pacific cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.4.1.3 Asia Pacific cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.2 Japan
    • 8.4.2.1 Key Country Dynamics
    • 8.4.2.2 Target Disease Prevalence
    • 8.4.2.3 Competitive Scenario
    • 8.4.2.4 Regulatory Framework
    • 8.4.2.5 Reimbursement Scenario
    • 8.4.2.6 Japan cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.4.2.7 Japan cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.4.2.8 Japan cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.3 China
    • 8.4.3.1 Key Country Dynamics
    • 8.4.3.2 Target Disease Prevalence
    • 8.4.3.3 Competitive Scenario
    • 8.4.3.4 Regulatory Framework
    • 8.4.3.5 Reimbursement Scenario
    • 8.4.3.6 China cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.4.3.7 China cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.4.3.8 China cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.4 India
    • 8.4.4.1 Key Country Dynamics
    • 8.4.4.2 Target Disease Prevalence
    • 8.4.4.3 Competitive Scenario
    • 8.4.4.4 Regulatory Framework
    • 8.4.4.5 Reimbursement Scenario
    • 8.4.4.6 India cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.4.4.7 India cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.4.4.8 India cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.5 South Korea
    • 8.4.5.1 Key Country Dynamics
    • 8.4.5.2 Target Disease Prevalence
    • 8.4.5.3 Competitive Scenario
    • 8.4.5.4 Regulatory Framework
    • 8.4.5.5 Reimbursement Scenario
    • 8.4.5.6 South Korea cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.4.5.7 South Korea cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.4.5.8 South Korea cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.6 Australia
    • 8.3.9.1 Key Country Dynamics
    • 8.4.6.2 Target Disease Prevalence
    • 8.4.6.3 Competitive Scenario
    • 8.4.6.4 Regulatory Framework
    • 8.4.6.5 Reimbursement Scenario
    • 8.4.6.6 Australia cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.4.6.7 Australia cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.4.6.8 Australia cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4.7 Thailand
    • 8.4.7.1 Key Country Dynamics
    • 8.4.7.2 Target Disease Prevalence
    • 8.4.7.3 Competitive Scenario
    • 8.4.7.4 Regulatory Framework
    • 8.4.7.5 Reimbursement Scenario
    • 8.4.7.6 Thailand cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.4.7.7 Thailand cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.4.7.8 Thailand cell viability assay market, by end-user, 2018 - 2030 (USD Million)
• 8.5 Latin America
  • 8.5.1 SWOT Analysis
    • 8.5.1.1 Latin America cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.5.1.2 Latin America cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.5.1.3 Latin America cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.5.2 Brazil
    • 8.5.2.1 Key Country Dynamics
    • 8.5.2.2 Target Disease Prevalence
    • 8.5.2.3 Competitive Scenario
    • 8.5.2.4 Regulatory Framework
    • 8.5.2.5 Reimbursement Scenario
    • 8.5.2.6 Brazil cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.5.2.7 Brazil cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.5.2.8 Brazil cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.5.3 Mexico
    • 8.5.3.1 Key Country Dynamics
    • 8.5.3.2 Target Disease Prevalence
    • 8.5.3.3 Competitive Scenario
    • 8.5.3.4 Regulatory Framework
    • 8.5.3.5 Reimbursement Scenario
    • 8.5.3.6 Mexico cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.5.3.7 Mexico cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.5.3.8 Mexico cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.5.4 Argentina
    • 8.5.4.1 Key Country Dynamics
    • 8.5.4.2 Target Disease Prevalence
    • 8.5.4.3 Competitive Scenario
    • 8.5.4.4 Regulatory Framework
    • 8.5.4.5 Reimbursement Scenario
    • 8.5.4.6 Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.5.4.7 Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.5.4.8 Argentina cell viability assay market, by end-user, 2018 - 2030 (USD Million)
• 8.6 MEA
  • 8.6.1 SWOT Analysis
    • 8.6.1.1 MEA cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.6.1.2 MEA cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.6.1.3 MEA cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.2 South Africa
    • 8.6.4.1 Key Country Dynamics
    • 8.6.2.2 Target Disease Prevalence
    • 8.6.2.3 Competitive Scenario
    • 8.6.2.4 Regulatory Framework
    • 8.6.2.5 Reimbursement Scenario
    • 8.6.2.6 Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.6.2.7 Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.6.2.8 Argentina cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.3 Saudi Arabia
    • 8.6.3.1 Key Country Dynamics
    • 8.6.3.2 Target Disease Prevalence
    • 8.6.3.3 Competitive Scenario
    • 8.6.3.4 Regulatory Framework
    • 8.6.3.5 Reimbursement Scenario
    • 8.6.3.6 Saudi Arabia cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.6.3.7 Saudi Arabia cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.6.3.8 Saudi Arabia cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.4 UAE
    • 8.6.4.1 Key Country Dynamics
    • 8.6.4.2 Target Disease Prevalence
    • 8.6.4.3 Competitive Scenario
    • 8.6.4.4 Regulatory Framework
    • 8.6.4.5 Reimbursement Scenario
    • 8.6.4.6 UAE cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.6.4.7 UAE cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.6.4.8 UAE cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.6.5 Kuwait
    • 8.6.5.1 Key Country Dynamics
    • 8.6.5.2 Target Disease Prevalence
    • 8.6.5.3 Competitive Scenario
    • 8.6.5.4 Regulatory Framework
    • 8.6.5.5 Reimbursement Scenario
    • 8.6.5.6 Kuwait cell viability assay market, by product, 2018 - 2030 (USD Million)
    • 8.6.5.7 Kuwait cell viability assay market, by application, 2018 - 2030 (USD Million)
    • 8.6.5.8 Kuwait cell viability assay market, by end-user, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

• 9.1 Participant's overview
  • 9.1.1 Thermo Fisher Scientific Inc.
  • 9.1.2 Agilent Technologies, Inc.
  • 9.1.3 Bio-Rad Laboratories Inc.
  • 9.1.4 Merck KGaA
  • 9.1.5 BD
  • 9.1.6 PerkinElmer Inc.
  • 9.1.7 Promega Corporation
  • 9.1.8 Biotium
  • 9.1.9 Creative Bioarray
  • 9.1.10 Abcam Plc
  • 9.1.11 Charles River Laboratories
• 9.2 Financial performance
• 9.3 Participant categorization
  • 9.3.1 Market leaders
    • 9.3.1.1 Cell viability assay market share analysis, 2022
  • 9.3.2 Strategy mapping
    • 9.3.2.1 Expansion
    • 9.3.2.2 Acquisition
    • 9.3.2.3 Collaborations
    • 9.3.2.4 Product/service launch
    • 9.3.2.5 Partnerships
    • 9.3.2.6 Others